ksx01
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 7, 2023 (NCT05811975)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Melanoma-associated antigen 4Immunity, passive
MAGEA4 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06150365 | Early Phase 1 (Phase 1) | Nov 7, 2023 | Chinese Academy of Medical Sciences |
| NCT05811975 | Early Phase 1 (Phase 1) | Mar 7, 2023 | Hacettepe University, TScan Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Hacettepe University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| TScan Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1